St. Lucia Offers ‘frictionless’ Virtual Citizenship Application Process
18.11.2020 12:00:00 EET | Business Wire | Press release
The St. Lucia Citizenship-by-Investment Unit (CIU) has launched the Caribbean region’s first, and currently only, e-payment platform. It enables international investors and their families to apply for the island nation’s investment migration programme entirely online, offering greater efficiency and reducing the processing time from application to the granting of citizenship. The e-payment platform has the capacity to receive all payments associated with the application, including the processing and due diligence fees; administrative fees for real estate and bonds, and the investment made into the National Economic Fund.
CEO Nestor Alfred says delivering a secure, transparent, fast, efficient, and professional service to high-net-worth global investors lies at the heart of St. Lucia CIU’s latest innovation developed by its internal IT team. “During the Covid-19-imposed international lockdown, arranging for bank wire transfer could either add weeks to the timeframe or be simply impossible for our investors to manage. This homegrown, wholly-owned and managed e-payment and processing platform is seamlessly integrated into our new website and will save our clients’ precious time as well as capital as there are no fees required to manage the transfer.”
St. Lucia offers various options to investors looking to secure citizenship of the country, starting at USD 100,000. In May, St. Lucia was the first Caribbean country to announce a new investment option in response to the coronavirus pandemic. To qualify for citizenship via the Covid-19 Relief Bond option, which currently runs until 31 December 2020, an individual is required to make a minimum investment of USD 250,000 in a non–interest-bearing government bond that must be held for five years.
In addition, St. Lucia recently made several key amendments to its legislation to make its citizenship-by-investment program even more attractive to investors with families. The category of ‘qualifying dependant’ has been expanded and now includes the option to “add-on” qualifying dependants in all investment options for the granting of citizenship. Besides your spouse, you can now include children up to the age of 30 as well as parents over 55 if they are fully supported by you. An unmarried sister or brother who is under 18 can also be included in your application.
As Alfred points out, the Caribbean island nation is intent on creating additional value for its international investors over and above the sustainable return that is guaranteed by St. Lucia CIU’s commitment to the highest standards of good governance. “We offer significant return on investment at a competitive investment level, with visa-free access to 146 destinations worldwide, but it’s our dedication to ensuring rigorous due diligence and accountability at the highest level across comparable options that really underpins this strategic investment. The long-term growth and legacy options offered by St. Lucia to international investors include lifelong yield for themselves and their dependents as well as ongoing and exponential value opportunities through enhanced global mobility.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201118005103/en/
Contact information
Media Contact:
Tajma Brown
St. Lucia Citizenship-by-Investment Unit
media@cipsaintlucia.com
+1-758-458-6050
www.cipsaintlucia.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom